মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole is contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using anastrozole. if anastrozole is used during pregnancy, or if the patient becomes pregnant while taking this drug

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - tamoxifen citrate - oral tablet - 20mg

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - tamoxifen citrate - oral tablet - 20mg

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

medsource pharmaceuticals - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole is contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using anastrozole. if anastrozole is used during pregnancy, or if the patient becomes pregnant while taking this drug

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

h.j. harkins company, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - 1.1 adjuvant treatment anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 first-line treatment anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 second-line treatment anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. 4.1 pregnancy and premenopausal women anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole is contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using an

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. hypersensitivity anastrozole is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. observed reactions include anaphylaxis, angioedema, and urticaria [see adverse reactions ( 6.2)]. risk summary based on findings from animal studies and its mechanism of action, anastrozole may cause

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - tamoxifen citrate -

মিশর - ইংরেজি - EDA (Egyptian Drug Authority)

sedico - coated tablet - 10 mg

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. hypersensitivity anastrozole is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. observed reactions include anaphylaxis, angioedema, and urticaria [see adverse reactions ( 6.2)]. risk summary based on findings from animal studies and its mechanism of action, anastrozole may cause fetal harm when administered

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - tamoxifen citrate - oral tablet - 20mg